Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Intervacc

0.68 SEK+0.89 %19/11 17:25
Less than 1K followers

IVACC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.89 %
-21.98 %
-39.25 %
-43.69 %
-26.62 %
-27.87 %
-86.76 %
-98.75 %
-87.75 %

Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its own technology platform with fused recombinant proteins. Sales are currently carried out through its own organization in the Nordic region and through its partner Dechra Pharmaceuticals in the rest of Europe. The company's headquarters are located in Hägersten.

Read more
Market cap
231.07M SEK
Turnover
307.92K SEK
Revenue
20.09M
EBIT %
-415.7 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Intervacc Q2: Net sales 1.9 M (SEK) Operating loss -18 M Net loss for the period -18 M To put it plainly, a total fiasco. International sales of the miracle vaccine are a ridiculous 160 thousand euros, which is on the same level as the turnover of some local car repair shop in Kajaani...
8/31/2023, 6:45 AM
by pt99659
7
Hello, a brand new interview with Intervacc’s new CEO Carl-Johan Dalsgaard about, among other things, the situation in the American market, challenges that must be overcome, and future prospects.
3/19/2026, 1:31 PM
by Isa Hudd
2
Its time will surely come. The product is very good in terms of its effectiveness; its need is just somewhat relative. Adoption takes its time. Sales are indeed slowly growing, but USA approvals are needed (as always in pharma) to truly make a profit. That will still take a couple...
10/14/2025, 5:19 PM
by Clark kent
2
Offering terms published. In a week, shares can be subscribed at a price of 4.10 SEK. Dilution 33%
5/16/2023, 8:37 AM
by pt99659
2
US approval will decide the fate of this stock. The product is good, but local trials still need to be executed correctly to obtain the approval. Additional expertise has been recruited to the management team and the board; let’s see how they perform. It will likely take a couple...
4/16/2026, 3:52 PM
by Clark kent
1
It’s interesting that the commercialization project for the vaccine product continues, with more countries in the distribution scope, etc. In itself, the company’s stock price is at rock bottom, if not below the basement floor. Inderes Intervacc and Dechra extend distribution agreement...
10/14/2025, 3:08 PM
by veronmaksaja
1
It is worth noting that the customer is conservative. The product is very good; the marketing work just needs to be done. For those with a risk tolerance, there are good opportunities to buy the stock. Those with lower risk tolerance should wait for US marketing authorization; there...
8/31/2023, 3:08 PM
by Clark kent
1
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17/2
2027

Annual report '26

Press release2026-11-17 15:14

Redeye: Intervacc (Q3 Intervju): Om Q3-rapporten

Intervacc
Press release2026-11-17 13:14

Redeye: Intervacc: Putting strangles on the map in the UK

Intervacc
Regulatory press release2026-11-16 08:00

Intervacc: Nytt rikstäckande varningssystem för kvarka lanseras i Storbritannien

Intervacc

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release2026-11-16 08:00

Intervacc: New UK-wide strangles alert scheme launched today

Intervacc
Press release2026-11-12 18:10

DNB Carnegie Access: Intervacc: Challenging quarter, US process on track – Q3 review

Intervacc
Regulatory press release2026-11-12 08:30

Delårsrapport januari - september 2026

Intervacc
Regulatory press release2026-11-12 08:30

Interim report January - September 2026

Intervacc
Press release2026-11-04 17:55

Redeye: Intervacc (Q3 Preview): Focus on upcoming catalysts

Intervacc
Press release2026-11-03 14:33

DNB Carnegie Access: Intervacc: Real-world data confirms strong Strangvac performance

Intervacc
Regulatory press release2026-11-03 08:30

Intervacc: Data från användning av Strangvac pekar på nära 100 procents skydd

Intervacc
Regulatory press release2026-11-03 08:30

Intervacc: Real-world Strangvac data shows nearly 100% protection

Intervacc
Press release2026-09-15 08:30

Intervacc to present at upcoming International Healthcare Conference

Intervacc
Press release2026-09-15 08:30

Intervacc presenterar vid kommande internationell life science-konferens

Intervacc
Press release2026-09-01 06:36

DNB Carnegie Access: Intervacc: Highlights from DNB Carnegie’s Micro Cap Day

Intervacc
Press release2026-08-24 11:26

Redeye: Intervacc (Q2 Review): Key catalysts nearing

Intervacc
Press release2026-08-21 08:24

DNB Carnegie Access: Intervacc: In the right direction – Q2 review

Intervacc
Press release2026-08-20 13:19

Redeye: Intervacc (Q2 initial take): Few surprises – all eyes on the label extension

Intervacc
Regulatory press release2026-08-20 08:30

Delårsrapport januari - juni 2026

Intervacc
Regulatory press release2026-08-20 08:30

Interim report January - June 2026

Intervacc
Regulatory press release2026-07-30 08:30

Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac

Intervacc